An official American Thoracic Society/European Respiratory Society statement: research questions in COPD

Bartolome R Celli, Marc Decramer, Jadwiga A Wedzicha, Kevin C Wilson, Alvar A Agustí, Gerard J Criner, William MacNee, Barry J Make, Stephen I Rennard, Robert A Stockley, Claus Vogelmeier, Antonio Anzueto, David H Au, Peter J Barnes, Pierre-Regis Burgel, Peter M Calverley, Ciro Casanova, Enrico M Clini, Christopher B Cooper, Harvey O Coxson, Daniel J Dusser, Leonardo M Fabbri, Bonnie Fahy, Gary T Ferguson, Andrew Fisher, Monica J Fletcher, Maurice Hayot, John R Hurst, Paul W Jones, Donald A Mahler, François Maltais, David M Mannino, Fernando J Martinez, Marc Miravitlles, Paula M Meek, Alberto Papi, Klaus F Rabe, Nicolas Roche, Frank C Sciurba, Sanjay Sethi, Nikos Siafakas, Don D Sin, Joan B Soriano, James K Stoller, Donald P Tashkin, Thierry Troosters, Geert M Verleden, Johny Verschakelen, Jorgen Vestbo, John W Walsh, George R Washko, Robert A Wise, Emiel F M Wouters, Richard L ZuWallack, ATS/ERS Task Force for COPD Research, Bartolome R Celli, Marc Decramer, Jadwiga A Wedzicha, Kevin C Wilson, Alvar Agustí, Gerard J Criner, William MacNee, Barry J Make, Stephen I Rennard, Robert A Stockley, Claus Vogelmeier, Antonio Anzueto, David H Au, Peter J Barnes, Pierre-Regis Burgel, Peter M Calverley, Ciro Casanova, Enrico M Clini, Christopher B Cooper, Harvey O Coxson, Daniel J Dusser, Leonardo M Fabbri, Bonnie Fahy, Gary T Ferguson, Andrew Fisher, Monica J Fletcher, Maurice Hayot, John R Hurst, W Jones, Donald A Mahler, François Maltais, David M Mannino, Fernando J Martinez, Marc Miravitlles, Paula M Meek, Alberto Papi, Klaus F Rabe, Nicolas Roche, Frank C Sciurba, Sanjay Sethi, Nikos Siafakas, Don D Sin, Joan B Soriano, James K Stoller, Donald P Tashkin, Thierry Troosters, Geert M Verleden, Johny Verschakelen, Jorgen Vestbo, John W Walsh, George R Washko, Robert A Wise, Emiel F M Wouters, Richard L ZuWallack, Bartolome R Celli, Marc Decramer, Jadwiga A Wedzicha, Kevin C Wilson, Alvar A Agustí, Gerard J Criner, William MacNee, Barry J Make, Stephen I Rennard, Robert A Stockley, Claus Vogelmeier, Antonio Anzueto, David H Au, Peter J Barnes, Pierre-Regis Burgel, Peter M Calverley, Ciro Casanova, Enrico M Clini, Christopher B Cooper, Harvey O Coxson, Daniel J Dusser, Leonardo M Fabbri, Bonnie Fahy, Gary T Ferguson, Andrew Fisher, Monica J Fletcher, Maurice Hayot, John R Hurst, Paul W Jones, Donald A Mahler, François Maltais, David M Mannino, Fernando J Martinez, Marc Miravitlles, Paula M Meek, Alberto Papi, Klaus F Rabe, Nicolas Roche, Frank C Sciurba, Sanjay Sethi, Nikos Siafakas, Don D Sin, Joan B Soriano, James K Stoller, Donald P Tashkin, Thierry Troosters, Geert M Verleden, Johny Verschakelen, Jorgen Vestbo, John W Walsh, George R Washko, Robert A Wise, Emiel F M Wouters, Richard L ZuWallack, ATS/ERS Task Force for COPD Research, Bartolome R Celli, Marc Decramer, Jadwiga A Wedzicha, Kevin C Wilson, Alvar Agustí, Gerard J Criner, William MacNee, Barry J Make, Stephen I Rennard, Robert A Stockley, Claus Vogelmeier, Antonio Anzueto, David H Au, Peter J Barnes, Pierre-Regis Burgel, Peter M Calverley, Ciro Casanova, Enrico M Clini, Christopher B Cooper, Harvey O Coxson, Daniel J Dusser, Leonardo M Fabbri, Bonnie Fahy, Gary T Ferguson, Andrew Fisher, Monica J Fletcher, Maurice Hayot, John R Hurst, W Jones, Donald A Mahler, François Maltais, David M Mannino, Fernando J Martinez, Marc Miravitlles, Paula M Meek, Alberto Papi, Klaus F Rabe, Nicolas Roche, Frank C Sciurba, Sanjay Sethi, Nikos Siafakas, Don D Sin, Joan B Soriano, James K Stoller, Donald P Tashkin, Thierry Troosters, Geert M Verleden, Johny Verschakelen, Jorgen Vestbo, John W Walsh, George R Washko, Robert A Wise, Emiel F M Wouters, Richard L ZuWallack

Abstract

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality and resource use worldwide. The goal of this official American Thoracic Society (ATS)/European Respiratory Society (ERS) Research Statement is to describe evidence related to diagnosis, assessment, and management; identify gaps in knowledge; and make recommendations for future research. It is not intended to provide clinical practice recommendations on COPD diagnosis and management. Clinicians, researchers and patient advocates with expertise in COPD were invited to participate. A literature search of Medline was performed, and studies deemed relevant were selected. The search was not a systematic review of the evidence. Existing evidence was appraised and summarised, and then salient knowledge gaps were identified. Recommendations for research that addresses important gaps in the evidence in all areas of COPD were formulated via discussion and consensus. Great strides have been made in the diagnosis, assessment and management of COPD, as well as understanding its pathogenesis. Despite this, many important questions remain unanswered. This ATS/ERS research statement highlights the types of research that leading clinicians, researchers and patient advocates believe will have the greatest impact on patient-centred outcomes.

Copyright ©ATS/ERS 2015.

References

    1. Celli BR, MacNee W, Agusti A, et al. . Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932–946.
    1. Vestbo J, Hurd SS, Agustí AG, et al. . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347–365.
    1. O'Reilly J, Jones MM, Parnham J, et al. . Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance. BMJ 2010; 340: c3134.
    1. Rostron BL, Chang CM, Pechacek TF. Estimation of cigarette smoking-attributable morbidity in the United States. JAMA Intern Med 2014; 174: 1922–1928.
    1. Jones P, Miravitlles M, van der Molen T, et al. . Beyond FEV1 in COPD: a review of patient-reported outcomes and their measurement. Int J Chron Obstruct Pulmon Dis 2012; 7: 697–709.
    1. Oga T, Nishimura K, Tsukino M, et al. . Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 2003; 167: 544–549.
    1. Coxson HO, Lam S. Quantitative assessment of the airway wall using computed tomography and optical coherence tomography. Proc Am Thorac Soc 2009; 6: 439–443.
    1. Copley SJ, Wells AU, Müller NL, et al. . Thin-section CT in obstructive pulmonary disease: discriminatory value. Radiology 2002; 223: 812–819.
    1. Coxson HO, Mayo J, Lam S, et al. . New and current clinical imaging techniques to study chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 588–597.
    1. Barr RG, Berkowitz EA, Bigazzi F, et al. . A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation. COPD 2012; 9: 151–159.
    1. Galbán CJ, Han MK, Boes JL, et al. . Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med 2012; 18: 1711–1715.
    1. Christe A, Charimo-Torrente J, Roychoudhury K, et al. . Accuracy of low-dose computed tomography (CT) for detecting and characterizing the most common CT-patterns of pulmonary disease. Eur J Radiol 2013; 82: e142–e150.
    1. Castaldi PJ, San José Estépar R, Mendoza CS, et al. . Distinct quantitative computed tomography emphysema patterns are associated with physiology and function in smokers. Am J Respir Crit Care Med 2013; 188: 1083–1090.
    1. Coxson HO, Leipsic J, Parraga G, et al. . Using pulmonary imaging to move COPD beyond FEV1. Am J Respir Crit Care Med 2014; 190: 135–144.
    1. Hardie JA, Buist AS, Vollmer WM, et al. . Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 2002; 20: 1117–1122.
    1. Cerveri I, Corsico AG, Accordini S, et al. . Underestimation of airflow obstruction among young adults using FEV1/FVC < 70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes. Thorax 2008; 63: 1040–1045.
    1. Bhatt SP, Sieren JC, Dransfield MT, et al. . Comparison of spirometric thresholds in diagnosing smoking-related airflow obstruction. Thorax 2014; 69: 409–414.
    1. Carlsson AC, Wändell P, Ösby U, et al. . High prevalence of diagnosis of diabetes, depression, anxiety, hypertension, asthma and COPD in the total population of Stockholm, Sweden – a challenge for public health. BMC Public Health 2013; 13: 670–678.
    1. Bridevaux PO, Gerbase MW, Probst-Hensch NM, et al. . Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax 2008; 63: 768–774.
    1. U.S. Preventive Services Task Force. Screening for chronic obstructive pulmonary disease using spirometry: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 148: 529–534.
    1. Ferrer M, Alonso J, Morera J, et al. . Chronic obstructive pulmonary disease stage and health-related quality of life. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group. Ann Intern Med 1997; 127: 1072–1079.
    1. Friedman M, Serby CW, Menjoge SS, et al. . Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999; 115: 635–641.
    1. Burge PS, Calverley PM, Jones PW, et al. . Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297–1303.
    1. Dewan NA, Rafique S, Kanwar B, et al. . Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest 2000; 117: 662–671.
    1. Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133: 14–20.
    1. Parshall MB, Schwartzstein RM, Adams L, et al. . An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 2012; 185: 435–452.
    1. Schols AM, Slangen J, Volovics L, et al. . Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1791–1797.
    1. Landbo C, Prescott E, Lange P, et al. . Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1856–1861.
    1. Mahler DA, Ward J, Waterman LA, et al. . Patient-reported dyspnea in COPD reliability and association with stage of disease. Chest 2009; 136: 1473–1479.
    1. Nishimura K, Izumi T, Tsukino M, et al. . Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434–1440.
    1. Celli BR, Cote CG, Marin JM, et al. . The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005–1012.
    1. Cote CG, Pinto-Plata VM, Marin JM, et al. . The modified BODE index: validation with mortality in COPD. Eur Respir J 2008; 32: 1269–1274.
    1. Soler-Cataluña JJ, Martínez-García MA, Sánchez LS, et al. . Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med 2009; 103: 692–699.
    1. Marin JM, Alfageme I, Almagro P, et al. . Multicomponent indices to predict survival in COPD: the COCOMICS study. Eur Respir J 2013; 42: 323–332.
    1. Celli BR, Locantore N, Yates J, et al. . Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185: 1065–1072.
    1. Puhan MA, Garcia-Aymerich J, Frey M, et al. . Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009; 374: 704–711.
    1. Jones RC, Donaldson GC, Chavannes NH, et al. . Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE index. Am J Respir Crit Care Med 2009; 180: 1189–1195.
    1. Divo M, Cote C, de Torres JP, et al. . Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 155–161.
    1. Almagro P, Soriano JB, Cabrera FJ, et al. . Short- and medium-term prognosis in patients hospitalized for COPD exacerbation: the CODEX index. Chest 2014; 145: 972–980.
    1. Agustí A, Barberà JA, Wouters EFM, et al. . Lungs, bone marrow, and adipose tissue. A network approach to the pathobiology of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 188: 1396–1406.
    1. Donaldson GC, Seemungal TAR, Bhowmik A, et al. . Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–852.
    1. Vestbo J, Edwards LD, Scanlon PD, et al. . Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011; 365: 1184–1192.
    1. Freimer N, Sabatti C. The human phenome project. Nat Genet 2003; 34: 15–21.
    1. Han MK, Agusti A, Calverley PM, et al. . Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182: 598–604.
    1. Drazen JM, Fabbri LM. Ageing and multimorbidity. Eur Respir J 2014; 44: 557.
    1. Faner R, Cruz T, López-Giraldo A, et al. . Network medicine, multimorbidity and the lung in the elderly. Eur Respir J 2014; 44: 775–788.
    1. Divo MJ, Martinez CH, Mannino DM. Ageing and the epidemiology of multimorbidity. Eur Respir J 2014; 44: 1055–1068.
    1. Patel AR, Donaldson GC, Mackay AJ, et al. . The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. Chest 2012; 141: 851–857.
    1. Mannino DM, Thorn D, Swensen A, et al. . Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962–969.
    1. de Torres JP, Marín JM, Casanova C, et al. . Lung cancer in patients with chronic obstructive pulmonary disease – incidence and predicting factors. Am J Respir Crit Care Med 2011; 184: 913–919.
    1. Wilson DO, Leader JK, Fuhrman CR, et al. . Quantitative computed tomography analysis, airflow obstruction, and lung cancer in the Pittsburgh lung screening study. J Thorac Oncol 2011; 6: 1200–1205.
    1. Vanfleteren LE, Spruit MA, Groenen M, et al. . Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 728–735.
    1. Donaldson GC, Hurst JR, Smith CJ, et al. . Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010; 137: 1091–1097.
    1. Bowler RP, Kim V, Regan E, et al. . Prediction of acute respiratory disease in current and former smokers with and without COPD. Chest 2014; 146: 941–950.
    1. Tan WC, Bourbeau J, Hernandez P, et al. . Exacerbation-like respiratory symptoms in individuals without chronic obstructive pulmonary disease: results from a population-based study. Thorax 2014; 69: 709–717.
    1. Marin JM, Soriano JB, Carrizo SJ, et al. . Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med 2010; 182: 325–331.
    1. Jha P, Peto R. Global effects of smoking, of quitting, and of taxing tobacco. N Engl J Med 2014; 370: 60–68.
    1. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166: 675–679.
    1. Parkes G, Greenhalgh T, Griffin M, et al. . Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ 2008; 336: 598–600.
    1. Bednarek M, Gorecka D, Wielgomas J, et al. . Smokers with airway obstruction are more likely to quit smoking. Thorax 2006; 61: 869–873.
    1. Stratelis G, Mölstad S, Jakobsson P, et al. . The impact of repeated spirometry and smoking cessation advice on smokers with mild COPD. Scand J Prim Health Care 2006; 24: 133–139.
    1. Kotz D, Wesseling G, Huibers MJH, et al. . Efficacy of confronting smokers with airflow limitation for smoking cessation. Eur Respir J 2009; 33: 754–762.
    1. Tashkin D, Kanner R, Bailey W, et al. . Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571–1575.
    1. Tashkin DP, Rennard S, Hays JT, et al. . Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 2011; 139: 591–599.
    1. Tønnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest 2006; 130: 334–342.
    1. Wagena EJ, van der Meer RM, Ostelo RJ, et al. . The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systematic review. Respir Med 2004; 98: 805–815.
    1. Wilson I. Depression in the patient with COPD. Int J Chron Obstruct Pulmon Dis 2006; 1: 61–64.
    1. Rigotti NA, Pipe AL, Benowitz NL, et al. . Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010; 121: 221–229.
    1. Ellerbeck EF, Mahnken JD, Cupertino AP, et al. . Effect of varying levels of disease management on smoking cessation: a randomized trial. Ann Intern Med 2009; 150: 437–446.
    1. Fiore MC, Jaen CR, Baker TB, et al. . Treating tobacco use and dependence: 2008 update. Clinical Practice Guidelines. Rockville, U.S., Department of Health and Human Services, 2008.
    1. Crowley TJ, Macdonald MJ, Walter MI. Behavioral anti-smoking trial in chronic obstructive pulmonary disease patients. Psychopharmacology (Berl) 1995; 119: 193–204.
    1. Etter J-F, Bullen C, Flouris AD, et al. . Electronic nicotine delivery systems: a research agenda. Tob Control 2011; 20: 243–248.
    1. Etter J-F, Bullen C. Electronic cigarette: users profile, utilization, satisfaction and perceived efficacy. Addiction 2011; 106: 2017–2028.
    1. Goniewicz MK, Lingas EO, Hajek P. Patterns of electronic cigarette use and user beliefs about their safety and benefits: an internet survey. Drug Alcohol Rev 2013; 32: 133–140.
    1. Bertholon JF, Becquemin MH, Annesi-Maesano I, et al. . Electronic cigarettes: a short review. Respiration 2013; 86: 433–438.
    1. Schraufnagel DE, Blasi F, Drummond MB, et al. . Electronic cigarettes. A position statement of the forum of international respiratory societies. Am J Respir Crit Care Med 2014; 190: 611–618.
    1. Buist AS, Sexton GJ, Nagy JM, et al. . The effect of smoking cessation and modification on lung function. Am Rev Respir Dis 1976; 114: 115–122.
    1. Jiménez-Ruiz C, Solano S, Viteri SA, et al. . Harm reduction – a treatment approach for resistant smokers with tobacco-related symptoms. Respiration 2002; 69: 452–455.
    1. Rennard SI, Daughton D, Fujita J, et al. . Short-term smoking reduction is associated with reduction in measures of lower respiratory tract inflammation in heavy smokers. Eur Respir J 1990; 3: 752–759.
    1. Simmons MS, Connett JE, Nides MA, et al. . Smoking reduction and the rate of decline in FEV1: results from the Lung Health Study. Eur Respir J 2005; 25: 1011–1017.
    1. Hughes JR, Carpenter MJ. Does smoking reduction increase future cessation and decrease disease risk? A qualitative review. Nicotine Tob Res 2006; 8: 739–749.
    1. Tetrault JM, Crothers K, Moore BA, et al. . Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med 2007; 167: 221–228.
    1. Calverley PM, Anderson JA, Celli B, et al. . Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–789.
    1. Tashkin DP, Celli B, Senn S, et al. . A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543–1554.
    1. Jenkins CR, Jones PW, Calverley PM, et al. . Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009; 10: 59.
    1. Burgel PR, Paillasseur JL, Dusser D, et al. . Tiotropium might improve survival in subjects with COPD at high risk of mortality. Respir Res 2014; 15: 64.
    1. Celli BR, Thomas NE, Anderson JA, et al. . Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332–338.
    1. Decramer M, Celli B, Kesten S, et al. . Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171–1178.
    1. Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 9: CD009157.
    1. Rabe KF, Fabbri LM, Israel E, et al. . Effect of ADRB2 polymorphism on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial. Lancet Respir Med 2014; 2: 44–53.
    1. Decramer ML, Chapman KR, Dahl R, et al. . Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med 2013; 1: 524–533.
    1. Calverley PM, Stockley RA, Seemungal TA, et al. . Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011; 139: 505–512.
    1. Crim C, Calverley PM, Anderson JA, et al. . Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009; 34: 641–647.
    1. Wedzicha JA, Calverley PM, Seemungal TA, et al. . The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177: 19–26.
    1. Aaron SD, Vandemheen KL, Fergusson D, et al. . Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146: 545–555.
    1. Wedzicha JA, Decramer M, Ficker JH, et al. . Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013; 1: 199–209.
    1. Magnussen H, Disse B, Rodriguez-Roisin R, et al. . Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014; 371: 1285–1294.
    1. Price LC, Lowe D, Hosker HS, et al. . UK National COPD Audit 2003: impact of hospital resources and organisation of care on patient outcome following admission for acute COPD exacerbation. Thorax 2006; 61: 837–842.
    1. Rutten FH, Zuithoff NP, Hak E, et al. . Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170: 880–887.
    1. Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD. Chest 2011; 139: 165–173.
    1. Spruit MA, Singh SJ, Garvey C, et al. . An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013; 188: e13–e64.
    1. Vieira DS, Maltais F, Bourbeau J. Home-based pulmonary rehabilitation in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 2010; 16: 134–143.
    1. Maltais F, Bourbeau J, Shapiro S, et al. . Effects of home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2008; 149: 869–878.
    1. van Wetering CR, Hoogendoorn M, Mol SJ, et al. . Short- and long-term efficacy of a community-based COPD management programme in less advanced COPD: a randomised controlled trial. Thorax 2010; 65: 7–13.
    1. van Wetering CR, Hoogendoorn M, Broekhuizen R, et al. . Efficacy and costs of nutritional rehabilitation in muscle-wasted patients with chronic obstructive pulmonary disease in a community-based setting: a prespecified subgroup analysis of the INTERCOM trial. J Am Med Dir Assoc 2010; 11: 179–187.
    1. Puhan MA, Gimeno-Santos E, Scharplatz M, et al. . Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011; 10: CD005305.
    1. Casaburi R, Kukafka D, Cooper CB, et al. . Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127: 809–817.
    1. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1: 681–686.
    1. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93: 391–398.
    1. Górecka D, Gorzelak K, Sliwiński P, et al. . Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia. Thorax 1997; 52: 674–679.
    1. Brochard L, Mancebo J, Wysocki M, et al. . Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995; 333: 817–822.
    1. Bott J, Carroll MP, Conway JH, et al. . Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. Lancet 1993; 341: 1555–1557.
    1. Kramer N, Meyer TJ, Meharg J, et al. . Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 1995; 151: 1799–1806.
    1. Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Lancet 2000; 355: 1931–1935.
    1. Nava S, Hill N. Non-invasive ventilation in acute respiratory failure. Lancet 2009; 374: 250–259.
    1. Bhatt SP, Peterson MW, Wilson JS, et al. . Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial. Int J Chron Obstruct Pulmon Dis 2013; 8: 581–589.
    1. Lamia B, Cuvelier A, Benichou J, et al. . Bénéfices de la ventilation non invasive a domicile au décours d'une insuffisance respiratoire aigue hypercapnique chez les patients BPCO. Etude contrôlée randomisée multicentrique. Etude Non Invasive Ventilation in Obstructive Lung Disease (Nivold) [A multi-centre randomized controlled trial of domiciliary non-invasive ventilation vs long-term oxygen therapy in survivors of acute hypercapnic respiratory failure due to COPD. Non-invasive ventilation in obstructive lung disease (NIVOLD) study]. Rev Mal Respir 2012; 29: 1141–1148.
    1. Clini E, Sturani C, Rossi A, et al. . The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. Eur Respir J 2002; 20: 529–538.
    1. Struik FM, Sprooten RT, Kerstjen HA, et al. . Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomized, controlled, parallel-group study. Thorax 2014; 69: 826–834.
    1. Struik FM, Lacasse Y, Goldstein RS, et al. . Nocturnal noninvasive positive pressure ventilation in stable COPD: a systematic review and individual patient data meta-analysis. Respir Med 2014; 108: 329–337.
    1. Kohnlein T, Windisch W, Kohler D, et al. . Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir Med 2014; 2: 698–705.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner